Rocket Pharmaceuticals Announces Participation at Upcoming Conferences - Sep 04, 2020
NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:
- Citi's 15th Annual BioPharma Virtual Conference
- Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Thursday, September 10, 2020, at 1:30 p.m. Eastern Time.
- Jonathan D. Schwartz, M.D., Chief Medical Officer and Senior Vice President, is scheduled to participate on a panel for Benign Hematology on Thursday, September 10, 2020, at 4:15 p.m. Eastern Time.
- Morgan Stanley’s 18th Annual Global Healthcare Virtual Conference
- Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Thursday, September 17, 2020, at 2:00 p.m. Eastern Time.
A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005151/en/
Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development
Source: Rocket Pharmaceuticals, Inc.
View this news release online at: